Vland Biotech released its performance for the first three quarters, with a net profit attributable to the parent company of 61.78 million yuan, a year-on-year increase of 51.24%

According to the Zhitong Finance APP, Vland Biotech disclosed its third-quarter report for 2025, stating that the company achieved revenue of 1.016 billion yuan in the first three quarters, a year-on-year increase of 7.42%; net profit attributable to the parent company was 61.78 million yuan, a year-on-year increase of 51.24%; net profit excluding non-recurring items was 22.93 million yuan, a year-on-year decrease of 1.47%; basic earnings per share were 0.24 yuan

Vland Biotech's subsidiary receives registration certificates for two joint applications of new veterinary drugs

According to the Zhitong Finance APP, Vland Biotech announced that, after review by the Ministry of Agriculture and Rural Affairs, the company's wholly-owned subsidiary Qingdao Kangdien Animal Pharmaceutical Co., Ltd. and other units jointly applied for "Fluralaner Drops (for Dogs)" and "Fluralaner Drops (for Cats)" to be classified as new veterinary drugs of Category II, and the "New Veterinary Drug Registration Certificate" was recently issued

Vland Biotech released its semi-annual performance report, with a net profit attributable to the parent company of 26.72 million yuan, a year-on-year decrease of 8.98%

According to the Zhitong Finance APP, Vland Biotech disclosed its semi-annual report for 2025, reporting revenue of 652 million yuan, a year-on-year increase of 7.05%; net profit attributable to the parent company of 26.72 million yuan, a year-on-year decrease of 8.98%; net profit excluding non-recurring items of 16 million yuan, a year-on-year increase of 4.17%; and basic earnings per share of 0.11 yuan

Vland Biotech: The company and its subsidiaries jointly applied for the registration certificate of the new veterinary drug for Mianping ointment, which has been approved

Vland Biotech announced that the company and its wholly-owned subsidiaries, Qingdao Vland Zhi Chong Biotechnology Co., Ltd. and Qingdao Kangdian Animal Pharmaceutical Co., Ltd., along with other units, jointly applied for the "Mirtazapine Ointment" as a Category V new veterinary drug, and recently received the "New Veterinary Drug Registration Certificate." This product is mainly used to control weight loss in cats, developed jointly by the company and its wholly-owned subsidiaries with multiple units, with a total R&D investment of RMB 1.8622 million. The acquisition of the new veterinary drug certificate is expected to bring new performance growth points to the company's business

Biological vaccine stocks strengthened, among which, Shen Lian Biomedical rose over 10%, Global Printing 10CM hit the daily limit, Guanhao Biotech and Sinovac Biotech rose over 7%, Saili Medical rose over 5%, Kanglao Weishi, Jinhe Biotechnology, and Vland Biotech rose over 4%, Yongshun Biotech, Dezhan Health, Junzheng Group, and Kanghua Biotech rose over 3%